MNC Products Retain Dominance In Korea As Local Generics Face Challenges
This article was originally published in PharmAsia News
SEOUL - Multinational company products covered by South Korea's national medical insurance system were the most prescribed last year, according to recent government data
You may also be interested in...
SEOUL - South Korea's Dong-A Pharmaceutical says its U.S. partner Warner Chilcott is seeking an expanded indication of lower urinary track symptoms for its erectile dysfunction drug Zydena (udenafil)
SEOUL - GlaxoSmithKline is paying KRW142.9 billion ($128.7 million) to acquire a 9.9 percent stake in South Korea's leading Dong-A pharmaceutical and OTC company. The strategic alliance should help GSK gain market share in the rapidly growing Korean pharmaceutical market
SEOUL - Last week's passage of long-awaited "anti-rebate laws" that enable courts to punish both contributors and receivers of rebates, could trigger more demand from doctors to prescribe branded products from multinational companies, industry watchers said